BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 23125448)

  • 21. Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.
    Cole LE; Li L; Jetley U; Zhang J; Pacheco K; Ma F; Zhang J; Mundle S; Yan Y; Barone L; Rogers C; Beltraminelli N; Quemeneur L; Kleanthous H; Anderson SF; Anosova NG
    Vaccine; 2019 Jun; 37(29):3892-3901. PubMed ID: 31122858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model.
    Cohen OR; Steele JA; Zhang Q; Schmidt DJ; Wang Y; Hamel PE; Beamer G; Xu B; Tzipori S
    PLoS One; 2014; 9(10):e111075. PubMed ID: 25347821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
    Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP
    Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.
    Wang Y; Wang S; Bouillaut L; Li C; Duan Z; Zhang K; Ju X; Tzipori S; Sonenshein AL; Sun X
    Infect Immun; 2018 Nov; 86(11):. PubMed ID: 30150259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors.
    von Eichel-Streiber A; Paik W; Knight K; Gisch K; Nadjafi K; Decker C; Bosnjak O; Cheknis A; Johnson S; von Eichel-Streiber C
    Anaerobe; 2016 Oct; 41():91-103. PubMed ID: 27427464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.
    Secore S; Wang S; Doughtry J; Xie J; Miezeiewski M; Rustandi RR; Horton M; Xoconostle R; Wang B; Lancaster C; Kristopeit A; Wang SC; Christanti S; Vitelli S; Gentile MP; Goerke A; Skinner J; Strable E; Thiriot DS; Bodmer JL; Heinrichs JH
    PLoS One; 2017; 12(1):e0170640. PubMed ID: 28125650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adaptive immune response to Clostridium difficile infection: A perspective for prevention and therapy.
    Rees WD; Steiner TS
    Eur J Immunol; 2018 Mar; 48(3):398-406. PubMed ID: 29272036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of the humoral immune response to Clostridium difficile toxins A and B in susceptibility to C. difficile infection: a case-control study.
    Islam J; Taylor AL; Rao K; Huffnagle G; Young VB; Rajkumar C; Cohen J; Papatheodorou P; Aronoff DM; Llewelyn MJ
    Anaerobe; 2014 Jun; 27():82-6. PubMed ID: 24708941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.
    Romano MR; Leuzzi R; Cappelletti E; Tontini M; Nilo A; Proietti D; Berti F; Costantino P; Adamo R; Scarselli M
    Toxins (Basel); 2014 Apr; 6(4):1385-96. PubMed ID: 24759173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease.
    Ghose C; Verhagen JM; Chen X; Yu J; Huang Y; Chenesseau O; Kelly CP; Ho DD
    Infect Immun; 2013 Jun; 81(6):2190-6. PubMed ID: 23545305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Murine Intrarectal Instillation of Purified Recombinant
    Markham NO; Bloch SC; Shupe JA; Laubacher EN; Thomas AK; Kroh HK; Childress KO; Peritore-Galve FC; Washington MK; Coffey RJ; Lacy DB
    Infect Immun; 2021 Mar; 89(4):. PubMed ID: 33468584
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model.
    Heidebrecht HJ; Weiss WJ; Pulse M; Lange A; Gisch K; Kliem H; Mann S; Pfaffl MW; Kulozik U; von Eichel-Streiber C
    Toxins (Basel); 2019 Feb; 11(2):. PubMed ID: 30736358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.
    Koon HW; Shih DQ; Hing TC; Yoo JH; Ho S; Chen X; Kelly CP; Targan SR; Pothoulakis C
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3214-23. PubMed ID: 23629713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enterotoxic Clostridia:
    Mileto S; Das A; Lyras D
    Microbiol Spectr; 2019 May; 7(3):. PubMed ID: 31124432
    [No Abstract]   [Full Text] [Related]  

  • 35. The enterotoxicity of Clostridium difficile toxins.
    Sun X; Savidge T; Feng H
    Toxins (Basel); 2010 Jul; 2(7):1848-80. PubMed ID: 22069662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile.
    Zhang BZ; Cai J; Yu B; Hua Y; Lau CC; Kao RY; Sze KH; Yuen KY; Huang JD
    BMC Infect Dis; 2016 Oct; 16(1):596. PubMed ID: 27770789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IgG antibody response to toxins A and B in patients with Clostridium difficile infection.
    Wullt M; Norén T; Ljungh A; Åkerlund T
    Clin Vaccine Immunol; 2012 Sep; 19(9):1552-4. PubMed ID: 22787196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.
    Guo S; Yan W; McDonough SP; Lin N; Wu KJ; He H; Xiang H; Yang M; Moreira MA; Chang YF
    Vaccine; 2015 Mar; 33(13):1586-95. PubMed ID: 25698490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.
    Zhang Y; Yang Z; Gao S; Hamza T; Yfantis HG; Lipsky M; Feng H
    Anaerobe; 2017 Dec; 48():249-256. PubMed ID: 29031928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A.
    He X; Sun X; Wang J; Wang X; Zhang Q; Tzipori S; Feng H
    Infect Immun; 2009 Jun; 77(6):2294-303. PubMed ID: 19307220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.